BIO Middle East

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Biologics

Medicines produced in or from living systems, such as monoclonal antibodies, recombinant proteins, vaccines and cell therapies, rather than by classical chemical synthesis. Biologics dominate the pipeline of the biotech and biopharma companies that exhibit and partner at Riyadh life-sciences events.

2

Biosimilar

A follow-on version of an already approved biologic that is licensed after demonstrating comparability in quality, safety and efficacy rather than repeating the full originator clinical programme. Gulf regulators, including the Saudi Food and Drug Authority, run dedicated biosimilar review pathways.

3

CDMO

Contract development and manufacturing organisation, a company that develops processes and manufactures drug substance or drug product for biotech sponsors that do not own a plant. CDMOs are a core exhibitor category at biotech partnering shows because they sell capacity and tech-transfer capability.

4

CRO

Contract research organisation, a service provider that runs preclinical studies, bioanalysis and clinical trials on behalf of a sponsor. At a Middle East edition, CROs typically pitch regional patient access and trial-site networks alongside global laboratory capacity.

5

Upstream and downstream processing

The two halves of biomanufacturing: upstream covers cell culture or fermentation where the molecule is produced, downstream covers recovery and purification through chromatography, filtration and viral inactivation. Equipment and consumables for both are core exhibition-floor product families.

6

Monoclonal antibody (mAb)

A laboratory-made antibody that binds a single epitope and is used across oncology, immunology and infectious disease. mAb programmes drive most large-scale mammalian cell culture capacity demand discussed in bioprocessing sessions.

7

Cell and gene therapy (CGT)

Therapies that deliver living cells or genetic material, including CAR-T, AAV and lentiviral vectors and mRNA-based approaches. CGT supply chains are short, temperature controlled and heavily regulated, which makes cold-chain and regulatory sessions high-attendance content.

8

mRNA platform

A drug modality in which a synthetic messenger RNA instructs the patient's cells to produce a protein or antigen, delivered in lipid nanoparticles. mRNA capability is usually discussed at regional biotech events in the context of local vaccine manufacturing and pandemic preparedness.

9

Expression system

The host organism used to manufacture a biologic, commonly CHO cells for antibodies, E. coli for simple proteins and yeast or insect cells for other modalities. Choosing an expression system is a central process-development decision and a frequent tech-transfer topic.

10

Tech transfer

The documented movement of a manufacturing process from one site or organisation to another, covering process characterisation, analytical methods, validation and regulatory filings. Tech transfer towards local Saudi manufacturing is a recurring theme in Gulf biopharma investment.

11

GMP compliance

Good Manufacturing Practice, the quality system that governs pharmaceutical production facilities, documentation, validation and personnel. Exhibitors promoting single-use bioreactors, cleanrooms or quality software position their products against GMP expectations.

12

Fill-finish

The final manufacturing step where bulk drug substance is filled into vials, syringes or cartridges, sealed and inspected under aseptic conditions. Fill-finish capacity is one of the capabilities Gulf governments have targeted for localisation.

13

Lyophilisation

Freeze-drying of a formulation to improve stability and shelf life, common for biologics and vaccines that cannot tolerate liquid storage. Lyophilisers and cycle-development services appear in the process-equipment segment of the floor.

14

Clinical trial phase

The staged testing of an investigational medicine: Phase I for safety and dosing, Phase II for efficacy signals, Phase III for confirmatory evidence and Phase IV for post-approval surveillance. Regional site networks and patient recruitment are the practical pitch from CROs at the show.

15

Saudi Food and Drug Authority (SFDA)

The Saudi regulator responsible for drug, biologic, medical device and food approvals, including clinical trial authorisation and post-market surveillance. Companies planning to sell in the Kingdom map their registration timeline against SFDA requirements before they commit to a distributor.

16

Local content and localisation

Saudi industrial policy that rewards manufacturing, R&D and service activity performed inside the Kingdom, applied through procurement preferences and incentive programmes. It shapes which CDMOs, suppliers and joint ventures exhibit in Riyadh.

17

Genomics and precision medicine

The use of sequencing and biomarker data to match therapies to patient populations. Population-scale genomics initiatives in the Gulf make this a standing conference topic alongside companion diagnostics and bioinformatics.

18

Companion diagnostic

A test that is co-developed with a therapeutic to identify which patients are likely to respond. It links the diagnostics and pharma sides of the exhibition floor and sits at the centre of regulatory discussions about biomarker validation.

19

Bioprocess single-use systems

Disposable bags, tubing, bioreactors and mixers that replace stainless-steel equipment for a single production campaign. They shorten changeover and validation time, which is a common argument for younger biotech plants in the region.

20

Partnering meetings

Pre-scheduled one-to-one business meetings arranged through the organiser's partnering platform, where licensors, investors and service providers book slots in advance. At biotech events these meetings, rather than the booth alone, are usually the primary commercial reason to attend.